Top Markets
Coin of the day
Novartis AG Novartis AG

Novartis AG

NVS
株式のランク #46
Novartis AG researches, develops, manufactures, and markets healthcare products... Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
株価
$150.75
時価総額
$291.41B
変化(1日)
1.44%
変化(1年)
40.17%
CH
取引 Novartis AG (NVS)

カテゴリー

Novartis AG(NVS)のP/S比率
2026 時点のP/S比率 TTM: 0
Novartis AG の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0 です。2026 年末時点でのP/S比率は 0 でした。
Novartis AG の P/S 比率の履歴(2026 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/S比率
企業 P/S比率 P/S比率の差
14.26 -
US
4.96 -
GB
6.18 -
US
6.35 -
US
4.40 -
US